188 results about "Uridine" patented technology

The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof ("uridine related compounds"). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods. In a preferred aspect the invention relates to a method of treatment of one or more side effects of statin therapy comprising administering to a subject in need of such treatment an effective amount of uridine, one of its biological precursors or a salt, ester, tautomer or analogue thereof either simultaneously, sequentially or separately to administration of an effective amount of at least one compound of Formula (I).

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

The invention belongs to the technical field of enzyme engineering, and concretely relates to a pyrimidine nucleoside high-yielding strain and a carbamyl phosphate synthetase adjusting site thereof. The invention provides a pyrimidine nucleoside production Bacillus subtilis mutant strain and a carbamyl phosphate synthetase encoding gene. A key regulation site related to carbamyl phosphate synthetase end product feedback inhibition is defined, and provides reference for breeding of later pyrimidine nucleoside high-yielding strains. The Bacillus subtilis mutant strain allows the output of fermentation process produced nucleoside pyrimidine uridine to reach 14-16g/L, and has substantially improved tolerance to different pyrimidine nucleoside structure analogs.

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.

The invention relates to a novel use of serum sample micromolecule metabolites such as oleic acid, stearic acid, eicosatrienoic acid, dehydroepiandrosterone sulfate, glycosylated phenylalanine and uridine as combined markers in preparation of a kit for diagnosis of polycystic ovarian syndrome of subjects. The invention also relates to a kit of diagnosis of polycystic ovarian syndrome of subjects. The kit is used for detecting respective concentrations of the combined markers in a serum sample of a female subject, calculating combined marker variable based on a binary logistic regression equation, and determining if the subject suffers from polycystic ovarian syndrome based on the determined intercept point value. The kit can realizes high sensitivity and high efficiency detection of the micromolecular metabolites and has the characteristics of low detection cost and good repeatability. Through combined use of the micromolecular metabolites, the kit can be used in auxiliary diagnosis of different symptoms of polycystic ovarian syndrome.

In one embodiment, the present application discloses a cell culture medium for culturing cell lines suitable for producing a therapeutic protein, comprising an amino acid selected from a group consisting of L-arginine, L-asparagine, L-proline, L leucine and L hydroxyproline and a mixture thereof; a vitamin selected from a group consisting of ascorbic acid Mg²⁺ salt, biotin, pyridoxine HCL, folic acid, riboflavin and D-calcium pantothenate, and a mixture thereof; an element selected from a group consisting of ammonium meta vanadate, sodium meta vanadate, germanium dioxide, barium acetate, aluminum chloride, rubidium chloride, cadmium chloride, ammonium molybedate, stannous chloride, cobalt chloride, chromium sulfate, silver nitrate, sodium metasilicate, zinc sulfate, manganese sulfate H₂O, manganous chloride, ferric nitrate 9H₂O, ferrous sulfate 7H₂O, ferric ammonium citrate, magnesium chloride anhydrous, and magnesium sulfate anhydrous, and a mixture thereof; a nucleoside selected from a group consisting of uridine and cystidine; a sugar selected from a group consisting of galactose, mannose and N-Acetyl-D-Mannosamine; and a triple buffering system comprising sodium carbonate, sodium bicarbonate and HEPES; wherein the cell culture medium is animal component-free, plant component-free, serum-free, growth factors-free, recombinant protein-free, lipid-free, steroid-free, and free of plant or animal hydrolysates and/or extracts.

The invention belongs to the field of traditional Chinese medicine composition analytic determination technology, and discloses a method for determining the contents of uridine, guanosine and adenosine in a rhizoma pinelliae medicinal material and decoction piece extract by a UPLC method. A chromatographic column is ACQUITY UPLC BEH C18 (1.7 [mu]m, 2.1*50 mm), a mobile phase is a water-methanol mixture with different-ratio gradient elution, a column temperature is 30 DEG C, the flow rate is 0.5 mL.min<-1>, and the detection wavelength is 254 nm. Uridine, guanosine and adenosine have good linear relationship in an applicable concentration range. The method is accurate, fast and reliable, and can effectively simultaneously determine the contents of uridine, guanosine and adenosine in the rhizoma pinelliae extract.

The invention belongs to the technical field of organic chemistry, and relates to a preparation method for (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine. The preparation method for (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine comprises the steps: with a protective fluororibose (represented by the formula I) as a starting material, carrying out a condensation reaction with a raw material ditrimethylsiyl protective uracil (represented by the formula VI) to obtain dibenzoyl uridine (represented by the formula IV), de-protecting dibenzoyl uridine to obtain the target product uridine (represented by the formula V), wherein a reaction equation is described in the specification. Compared with the prior art, the method reduces one reaction step in synthesis steps firstly, improves the production efficiency in the large-scale production, reduces the workload, reduces energy consumption and three-waste emission load, and improves the total yield of preparing the compound represented by the formula V from the compound represented by the formula I.

The invention discloses a novel method for measuring the nucleotide content in infant formula milk powder. The method comprises the following steps of: dissolving an infant formula milk powder sample in water; adjusting the pH to 4.6 with a formic acid solution; precipitating proteins in the sample; ultrasonically extracting, centrifuging and filtering; separating five types of nucleotides, i.e. CMP (Cytidine), AMP (Adenosine), UMP (Uridine), GMP (Guanosine) and IMP (Inosine) in a filtrate with a reversed phase chromatographic column; performing tandem mass spectrum; scanning in a multiple reaction monitoring (MRM) scanning mode; and quantifying with a substrate by using an external reference method. In the invention, five types of nucleotides in the infant formula milk powder are measured with an LC-MS/MS (Liquid Chromatogram-Mass Spectrometry/Mass Spectrometry) method, so that the using quantity of the sample is extremely small in an ESI (Electrospray Ionization) mode, an ion source is prevented from being polluted easily, and high sensitivity and low detection limit are realized. In particular, the MRM method is adopted, interference of non-nucleotide molecular ions can be well eliminated; and meanwhile, the method has the advantages of simple sample pretreatment and wide application range.

The invention provides hollow molecularly imprinted polymers which are modified by phenylboronic acid and an extraction column which is made by adopting the polymers. According to the synthetic method of the polymers, 3-aminophenylboronic acid is used as a modifying agent to conduct chemical modification on methacrylic acid monomers, uridine is used as a template, the modified methacrylic acid is used as functional monomers, matrixes, crosslinking agents and initiating agents are added to prepare molecularly imprinted materials, the prepared molecularly imprinted materials are subjected to template elution, the matrixes are corroded by adopting hydrofluoric acid, and the hollow molecularly imprinted polymers are obtained. The provided boron affinity hollow molecularly imprinted solid phase column has obvious enrichment effects on nucleoside type materials mainly due to the fact that molecular imprints conduct preferential adsorption on template molecules and structural analogues, and most binding sites of the hollow molecular imprints are distributed on surfaces of carrier matrix materials and in the hollow cavities and thus the adsorption efficiency is improved; furthermore, boric acid groups can carry out reversible adsorption and dissociation on the nucleoside type materials of a cis-diol structure, and therefore the boron affinity hollow molecularly imprinted solid phase column has obvious enrichment effects on the nucleoside type materials.

The present invention relates to a fingerprint for controlling quality of Chinese medicinal material isatis root and its medicinal preparation and its making method. Said invented fingerprint is one of antiviral active site in Chinese medicinal material isatis root, and said active site uses nucleosides as main composition portion, in which the known nucleoside components have adenosine, uridine and guanosine. Said invention utilizes the creation of fingerprint of active site of isatis root and combines it with quantitative analysis result of index components so as to comprehensively evaluate the quality and medicinal effect of isatis root and its medicinal preparation, and can make the quality of isatis root and its medicinal preparation have true controllable standard.

Nanoparticles having one or more attached sensing moieties including uridine 5′-triphosphate (UTP) and deoxythymidine 5′-triphosphate (dTTP), are disclosed herein. These nanoparticles can, for example, be used for detection of plasticizers, such as phthalates, in the sample. Methods, kits and apparatuses using these nanoparticles for detecting plasticizers in a sample are also disclosed herein.

The invention discloses a method for improving the yield of L-arginine synthesized by corynebacterium crenatum, specifically discloses a method for improving the yield of L-arginine through integratedmutation modification of bi-functional uridyl transfer/removal enzyme GlnD, modification of pII signal transduction protein GlnK and uridine acylation of GlnK, and belongs to the technical field of bioengineering. The method successfully achieves the integrative mutation modification of the bifunctional uridyl transfer/removal enzyme GlnD, the pII signal transduction protein GlnK is overexpressedon this base, and the uridine acylation of GlnK is enhanced. A 5-L fermentation tank is used for batch fermentation, the fermentation conditions are optimized, finally the final recombinant corynebacterium crenatum Cc-HDAA/pXMJ19-glnK is fermented for 96 h, the yield of L-arginine of the recombinant bacteria reaches 52.2 g/L, the production intensity reaches 0.544 g/L h, and the high yield of L-arginine is achieved.

The invention provides a milk powder of an immune formula. Each 100g of milk powder comprises the following components: 20-50g of a raw milk extract, 30-55g of demineralized whey powder, 5-20g of vegetable oil, 0.5-6g of probiotics, 20-100mg of inositol, 10-60mg of taurine, 8-50mg of L-carnitine and/or salt of L-carnitine, 50-150mg of choline matters and 15-45mg of nucleotide, wherein a weight ratio of five nucleotides including guanosine 5'-monophosphate disodium salt, cytidine 5'-monophosphate disodium salt, uridine-5'-monophosphate disodium salt, adenosine 5'-monophosphate disodium salt and guanosine 5'-monophosphate disodium salt is 1 to (0.1-10) to (1-5) to (0.1-5) to (0.1-3). The milk powder is relatively reasonable in formula ratio, and provides relatively complete nutrients and good absorption for infants, and the immunity of the infants is completely improved; meanwhile, components of maltodextrin, saccharose or white granulated sugar, essence, a pigment, an emulsifying agent and the like are not added, and thus the health of the infants is relatively facilitated.